US/UK/Canada

Share

Links

Quotes

This order is of strategic importance for Attana, since we are now involved at an early stage in designing R&D projects for a major drug development project. The order shows a market acceptance for our technology and capability to characterize interactions with cells, tissues, viruses etc it also provides a value of our application knowledge and the advises we can provide.
International Sales Manager Thomas Ljungberg
Pick a time period -
Tags ( Active)

New article using Attana's technology from National University of Singapore: Immunity differences in vaccinated individuals according to age, gender, lifestyle and other diseases

The article  presented quantification of serological immunity against SARS-CoV-2 variants. Differences in immunity are seen against the different variants and depending on age, sex, ethnicity and lifestyle, but e.g. high blood pressure or BMI did not show significant differences in the serological immunity of individuals vaccinated against the Wuhan variant. The study also showed poorer immunity to Omicron than to Wuhan, but after the third vaccine dose, an increased cross-reactivity between the different covid variants was shown.To

Attana and Linnaeus University have published the first part of the science behind immunity profiles

In the International Journal of Molecular Science , Attana and Linnaeus University have published the validation of Attana's QCM technology for IgG detection and determination for in-vitro diagnostics. The technique has been validated against electrochemiluminescence immunoassay (ECLIA) and chemiluminescence immunoassay (CLIA). The results in this publication are an important part in the development of Attana's immunity profiles.In the publication Quartz Crystal Microbalance Platform for SARS-CoV-2 Immuno-Diagnostics, Attana's QCM technology has

Attana’s presentation from Småbolagsdagarna is now available on YouTube

On June 14, Attana attended Aktiespararna’s Småbolagsdagarna where CEO, Teodor Aastrup, gave a 20-minute-long presentation followed by a 10-minute-long Q&A.The presentation was held in Swedish and primarily focused on Attana’s history and milestones, followed by Attana’s ongoing work within both its business areas – Life Science and Diagnostics. The presentation concluded with Attana long-term, 2030 plan. The presentation can be accessed by following this link: Attana – Småbolagsdagarna 2022 

Attana now offers self sampling for expanded diagnostic testing capabilities with an updated CE IVD-marking

Attana now enables self sampling through an updated CE IVD-marking for capillary blood samples using Capitainer[®]qDBS cards (quantitative dried blood spot), enabling laboratories improved opportunities to perform immune profiling and monitoring of vaccine efficacy in broad patient populations.As presented together with Capitainer in February 2022, the goal of Attana Diagnostics is to offer broader and more patient-centric blood sampling solutions for the Attana AVA[TM] system. Since then, Attana has validated its AVA[TM] SARS-CoV-2 IgG Immunoassay kit for capillary blood samples, both qDBS

Attana inks microsampling collaboration with Capitainer for improved diagnostic sampling

Combining Attana’s advanced biosensor system with Capitainer’s DBS home sampling makes immune profiling and vaccine efficacy monitoring possible in broad patient populations.Swedish bio- and healthtech companies Attana AB and Capitainer AB have signed an agreement with the goal of offering broader and more patient-centric blood sampling solutions for the Attana AVA[TM] system starting with COVID-19 immune profiling. Since November 2021, Attana has been performing comparative studies of finger stick capillary blood samples simultaneously collected by both test tubes and Capitainer®qDBS

Attana has signed a collaborative research agreement with a leading US academic medical center for biomedical research

Attana can today announce that a collaborative research agreement has been signed with one of the leading US academic medical centers for biomedical research.Attana AB has today signed a collaborative research agreement with one of the leading US academic medical centers within biomedical research, focusing on viruses and antibodies. Under the terms of the agreement, Attana will appoint personnel and an Attana Cell[TM] 250 instrument in the United States during Q1. The initial project scope will be performed through mid-June 2022 and can be mutually extended until the end of 2025. The aim

Attana’s presentation from Biotech Showcase 2022 is now available on Attana’s website

January 10–19, Attana is participating in one of the largest biotech conferences in the world – Biotech Showcase. Attana is attending the digital conference and have published a presentation as well as participated in digital one-to-one meetings.The presentation was held in English and primarily focused on Attana’s ongoing diagnostic work and its two business units – Life Science and Diagnostics. The presentation can be accessed on Attana’s website by following this link: Attana – Biotech Showcase 2022 

Attana and Triolab sign distribution agreement for all Attana products on the Swedish market

Attana can today announce that the company has signed a distribution agreement with Triolab AB for the marketing and sales of all Attana products on the Swedish market.In June, Attana and Triolab signed a memorandum of understanding (MOU) for the distribution of the newly launched Attana Diagnostics products. Since then, the parties have performed joint sales and marketing activities towards select customers in Sweden. Today, the companies have signed a distribution agreement for the Swedish market which includes all products within both Attana business units: Diagnostics and Life

Update following Attana’s participation at the Drug Discovery V-Forum

On April 21, Attana participated in the conference Drug Discovery V-Forum to present the company and listen in to presentations from other companies within the Life Science industry.This marked yet another conference where Attana had the opportunity to communicate its products and services to potential customers and partners. The company also presented preliminary results from the ongoing work with Attana Diagnostics and the development of a SARS-CoV-2 immunoassay. Attana’s recorded presentation can be found here .

Information about Attana’s presentation at Stora Aktiedagen streamed live on December 2[nd] 09:00-09:30

Attana will participate at Stora Aktiedagen where CEO Teodor Aastrup will give a 20-minute company presentation followed by a 10-minute Q&A session. Both will be live streamed on December 2[nd] from 09:00 to 09:30.The presentation will focus on where Attana stands today, where the company is heading and the plan for getting there. This includes a presentation of the exciting projects planned for 2021, enabled by the upcoming rights issue. Tentative schedule: 1. Attana in short– Attana’s product and service offering 2. Recent milestones– Important milestones during 2020 3.

Attana and ExpreS[2]ion Biotech have signed a Development & Supply Agreement

Attana AB (“Attana”) hereby announces that it has signed a heads of terms agreement regarding the development and supply of novel proteins from ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion"). The first target protein will be the ExpreS[2]ion-produced SARS-CoV-2 spike and receptor-binding-domain (RBD) antigen used in ExpreS[2]ion’s COVID-19 vaccine program. Attana will now be able to offer customers utilising its AVA diagnostic platform, this and other novel ExpreS[2]ion proteins. The parties are not disclosing the commercial terms of the agreement.In early June, ExpreS[2]ion announced (

Release of initial Attana Virus Analytics-AVA testing protocols

Attana has today released the initial technical protocols for AVA Antibody Testing and will make these available to all existing Attana customers.In close collaboration with Linnaeus University Attana application specialists have been performing studies on serum samples to detect and characterize COVID-19 antibodies using the Attana Cell™ 200 system. By optimizing the testing procedures, two protocols have now successfully been established and preparations are being made for the scientific publication of corresponding technical notes. The AVA Antibody-Testing protocols are comprised of

Attana launches the Attana Cell 250

Attana has today launched the Attana Cell 250 instrument which features a new and fully integrated autosampler, delivering vastly improved sample handling and instrument operation.Since 2019, Attana has been working closely with ModuVision Technologies BV (Vlissingen, The Netherlands) to integrate their flagship product, the PRIMARIZ robotic autosampler, into the Attana system. The Attana Cell 250 is the first result of this cooperation. “We are proud to welcome Attana to our ever-growing customer base and with this, enter into new application fields,” comments Jan Willem Mol, CEO of

Attana introduces Attana Virus Analytics to support global COVID-19 testing efforts

Since the advent of the COVID-19 outbreak Attana has been engaged by select customers to assist in their development of novel vaccine candidates and potential virus treatments. In these efforts, Attana instruments have routinely been used to analyze serum samples in real time, generating in-depth data of both virus and antibody presence. Given the strong global demand for COVID-19 testing and in particular, accurate antibody testing, Attana has introduced Attana Virus Analytics (AVA) and commenced discussions with various potential customers including international government entities

Potential COVID-19 vaccine passes important milestone

Since March, Attana has been assisting the team of Prof Ali Salanti at the University of Copenhagen in their development of a COVID-19 vaccine together with the Prevent-nCov consortium. Their vaccine is based on the Capsid Virus-Like Particle (cVLP) technology where coronavirus antigens are attached to the cVLP allowing the body’s immune system to respond to the antigens and produce antibodies.During the past two months the vaccine has been tested in mice which produced large amounts of antibodies able to neutralize SARS-CoV-2 virus and the response was several hundred times stronger than

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe